申请人:CL Pharma Aktiengesellschaft
公开号:US04841065A1
公开(公告)日:1989-06-20
Substituted isoxazoles of the formula ##STR1## in which R.sub.1 denotes C.sub.1 -C.sub.4 alkyl, R.sub.2 denotes hydrogen, C.sub.1 -C.sub.4 alkyl chlorine or bromine, R.sub.3 and R.sub.4, which are the same or different are hydrogen or C.sub.1 -C.sub.4 alkyl, but not both hydrogen and n denotes the interger 6, 7, or 8. The novel ocmpounds have a pronounced antiviral action and can be employed for the treatment and prophylaxis of virus diseases.
公式为##STR1##的取代异噁唑化合物,其中R.sub.1代表C.sub.1 -C.sub.4烷基,R.sub.2代表氢,C.sub.1 -C.sub.4烷基,氯或溴,R.sub.3和R.sub.4,相同或不同,代表氢或C.sub.1 -C.sub.4烷基,但不能同时为氢,n代表整数6、7或8。这些新化合物具有明显的抗病毒作用,可用于治疗和预防病毒性疾病。